Calyx and Invicro are now Perceptive
Independent review of trial event assessments by adjudication experts.
Proven expertise in delivering high-quality imaging data at a global scale.
With strengths in instrument engineering, signal processing, and pharmaceutical R&D, Perceptive Discovery consistently delivers successful imaging study designs and executions.
Effective RTSM, built on 30 years of experience, and connected to an ecosystem which includes eConsent and eCOA.
Highly established imaging centers for first-in-human and multicenter trials.
900+ agents radiolabeled and counting.
Supporting both malignant and non-malignant indications.
Experts in Alzheimer’s Disease, Parkinson’s Disease imaging and more.
Supporting over 85% of radiopharmaceutical companies.
Optimize preclinical and clinical trials in other areas and drug classifications.
Therapeutic and technical expertise in imaging modalities, protocol design, and acquisition.
Oncology imaging, RTSM, and clinical adjudication services.
Tackling unique rare disease trial supply, imaging and adjudication challenges.
We are here to serve science.
From discovery, through early to late-phase clinical development, to regulatory approval and post-market, you can count on Perceptive to be dependable, diligent, and driven in everything we do.
Perceptive Discovery bridges preclinical insights to early clinical success, ensuring rigorous scientific analysis and high-quality data to support innovation.
Providing the right-fit randomization & trial supply management solution for your trials, delivered by experts.
The right people, experience, and technology to drive clinical trial imaging success.
While traditional imaging methods like FDG-PET are effective for detecting highly metabolic cancer cells, they fall short in specifically imaging the tumor microenvironment. Fibroblast Activation Protein (FAP)-targeted PET imaging addresses this by specifically visualizing the tumor stroma, which is richly populated with cancer-associated fibroblasts. This targeted approach introduces a new dimension in tumor evaluation, with applicability across a wide range of cancers.
Moreover, the high expression of FAP in fibrotic diseases further highlights its broad utility as a biomarker across diverse pathological conditions. FAP inhibitors (FAPI) enable non-invasive imaging of FAP, providing enhanced diagnostic precision while unlocking theranostic potential in both oncology and fibrotic disease applications.
Moderator: Paulo Rosado de Castro MD, PhD
Medical Director at Perceptive
Co-founder, President, and CSO, Ratio Therapeutics
Associate Professor, Department of Molecular and Medical Pharmacology; Director, Theranostics Program, David Geffen School of Medicine at UCLA
Professor of Nuclear Medicine, Universitätsmedizin Essen, Universität Duisburg-Essen, Germany
Chief Scientific Officer, SOFIE
Complete the form below to access the recording.
Δ
